“Breaking Ground: Lenmeldy’s Approval and the Future of MLD Treatment”

Metachromatic leukodystrophy (MLD), a lesser-known disease, is a critical focus in the study of lysosomal storage disorders. It is inherited in an autosomal recessive manner. ARSA and PSAP genes are primarily responsible for this, as they mutate, leading to a shortage of available arylsulfatase A lysosomal enzyme and sphingolipid activator protein (SapB), respectively. Without this enzyme and protein, sulfatides accumulate as metachromatic granules in cells of the nervous system, such as oligodendrocytes and Schwann cells, and hinder myelin production, paving the way for demyelination. Demyelination gives rise to a plethora of symptoms, including but not limited to: motor function impairment, ataxia, optic atrophy, spasms, and impaired cognition (1,2,3). MLD is diagnosed best by the detection of mutations by sequencing. However, it can also be diagnosed by checking how much sulfatides are present in the patient’s urine and plasma, brain MRI, biochemical tests for ARSA enzymatic activity, and even by evaluating peripheral nerve size using ultrasound as well as clinical manifestations (1,4). While MLD is a rare disease, it is still one of the foremost leukodystrophies worldwide, found in 1 in every 40,000–160,000 (1). However, owing to its rarity and the many unknowns surrounding this disease, there have been no authorized treatments for MLD, with supportive care being the only management option. Despite these challenges, a breakthrough has emerged in the form of Lenmeldy gene therapy, recently approved by the FDA on March 18, 2024 (5). This gene therapy, the first of its kind to be approved by the FDA, offers hope to individuals with MLD and their families for a better quality of life and potentially improved outcomes. In this commentary, we will delve deeper into the FDA’s approval of Lenmeldy gene therapy and its implications for the future treatment of MLD.